Diabetes drug showdown: which combo works best for obese patients?

NCT ID NCT07531108

Completed Disease control Sponsor: Hawler Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different diabetes treatments in 186 overweight or obese adults newly diagnosed with type 2 diabetes. Participants received either empagliflozin plus metformin, sitagliptin plus metformin, or metformin alone for 12 weeks. Researchers measured changes in blood markers called omentin-1 and resistin, along with blood sugar and weight, to see which combination worked best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin, Sitagliptin, and Metformin (oral diabetes drugs)
What this could lead to: If successful, this could help doctors choose the best initial drug combination for obese patients with type 2 diabetes, potentially improving blood sugar control and weight management.
What could go wrong: This is a small, completed Phase 4 study in one city in Iraq, so results may not apply to all populations. The main focus was on blood markers, not long-term health outcomes like heart disease or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Galyawa Teaching Center for Diabetes and Endocrinology

Erbil, 44001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.